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ABSTRACT 
This study sought to determine whether a cannabidiol derivative, CBD-val-HS, could 
attenuate the development of oxycodone reward while retaining its analgesic effects. In 
Experiment 1) animals were enrolled in the conditioned place preference paradigm and received 
either saline or oxycodone in combination with one of four doses of CBD-val-HS using 3 sets of 
drug-/no drug-conditioning trials. Experiment 2) sought to determine whether a dose of CBD-
val-HS that blocks opioid reward administered alone or in combination with a sub-analgesic or 
analgesic doses of oxycodone would affect nociceptive processes in the hotplate and abdominal 
writhing assays. Results from this study demonstrated CBD-val-HS can attenuate the rewarding 
effects of oxycodone place preference at 8.0 mg/kg and it is void of rewarding or aversive 
properties. Further, CBD-val-HS alone produced analgesic effects in both nociceptive assays but 
was most effective when compared to oxycodone against thermal nociception.  Interestingly, 
there was a differential interaction of CBD-val-HS+oxycodone across the two nociceptive assays 
producing subadditive responses on the hotplate assay while additive responses were observed in 
the abdominal writhing assay. These findings suggest CBD-val-HS, a non-addicting analgesic 
compound, could prove useful in pain management and addiction treatment settings.  
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CHAPTER 1 
 
INTRODUCTION 
PAIN  
Pain is a biological response to noxious stimuli in our environment that initiates escape 
responses from painful stimuli and is critical for survival. Pain is defined as “an unpleasant 
sensory and emotional experience associated with actual or potential tissue damage” (“IASP 
Taxonomy,” 2016). Over 100 million Americans suffer from pain daily accounting for 80% of 
physician visits (Voscopaoulos & Lema, 2010; Pain: Hope through research,” 2016; Li & Zhang, 
2012). The economic burden of pain in the United States is estimated to be $636 billion annually 
due to treatment, loss of productivity, and long-term disability (Li & Zhang, 2012; “Relieving 
pain in America,” 2011; Nahin, 2015). Depending on the intensity and duration of a noxious 
stimulus (Voscopaoulos & Lema, 2010) pain can become insufferable, diminishing the quality of 
life. 
Depending on the duration of healing, pain can be either acute or chronic. Acute pain is 
caused by sudden activation of pain nociceptors. Noxious stimuli in acute pain are identifiable 
and allow immediate removal of the stimulus oftentimes resolving within 3 weeks 
(Voscopaoulos & Lema, 2010; Barkin & Barkin 2001). Common types of acute pain include 
upper respiratory tract infections, headache, tooth pain, and post-operative surgical pain (Rice, 
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Smith, & Blyth, 2016; “Fact sheets,” 2016).  In chronic pain, nociceptor pathways remain active 
after a noxious stimulus is removed and persists after a reasonable time for tissue to heal. 
Chronic pain can last for 12 weeks or longer (Benzon et al., 2011).  According to the American 
Academy of pain, 1.5 billion individuals worldwide are affected by chronic pain with cancer 
pain, neuropathy, and arthritis the most common (Dale & Stacey, 2016).  Pain is a multifaceted 
disorder with a variety of etiologies (Li & Zhang, 2012) and pharmacological treatments. 
OPIOIDS 
 Pharmacotherapies for treating pain include non-steroidal anti-inflammatory (NSAIDs), 
antidepressants, anticonvulsants, and opioids. Opioids are highly efficacious and are considered 
the “Gold Standard” in pain treatment (Li & Zhang, 2012). The family of opioids can be divided 
into opioids and opiates. Opiates are alkaloids derived from the opium poppy plant and include 
Morphine, Codeine, Heroin, and Opium. Opioids are synthetic or partly synthetic drugs that 
mimic the actions of opiates.  These include hydrocodone, fentanyl, and oxycodone. Opioids 
show high efficacy in treating a wide range of pain related injuries and diseases and are the most 
prescribed treatment for chronic pain. 
Opioids produce analgesia through binding to opioid receptors located throughout the 
peripheral and central nervous system (CNS). Mu and kappa receptors are located in the 
periaqueductal gray (PAG) while delta receptors in structures of the forebrain and hindbrain 
(Toll et al., 2015). The PAG projects to limbic targets upstream to modulate emotional pain, and 
downstream to the nucleus raphe magnus, and terminate on pain inhibitory neurons in the dorsal 
horn of the spinal cord (Ossipov, Dussor, & Porreca, 2010).  
Opioid binding to the PAG enhances descending inhibition and releases neurotransmitters 
(NT) that stimulate inhibitory interneurons in the dorsal horn. Binding leads to inhibition of the 
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afferent pain fiber and blocking the transmission of pain neurotransmitters calcitonin gene-
related peptides (cGRP), glutamate, and Substance P (Sub P) and ultimately block pain impulses 
and produce analgesia (Williams, 2008; Ossipov, Dussor, & Porreca, 2010). Although highly 
efficacious in treating pain, opioids are not without shortcomings. Because opioid receptors are 
abundantly found in the PNS and CNS, they can produce a number of side effects that limit their 
therapeutic use. 
Side effects 
Approximately 80% of patients treated with opioids suffer from adverse side effects 
(Kalso, 2004) that diminish quality of life.  Further, drugs with selectivity to specific opioid 
receptors produce their own set of side effects.  Most opioid analgesics are mu receptor agonists 
and produce side effects of sedation, vomiting, respiratory depression, nausea, and sleep 
disturbances as well as constipation. The magnitude of these side effects often depends on short 
or long term use (Cepeda, 2003; Benyamin et al., 2008).  
The greatest concern when prescribing opioids is respiratory depression and this side 
effect is common in acute opioid use (Dahan, Aarts, & Smith, 2010).  Opioids affect respiratory 
centers that receive peripheral inputs from chemoreceptors responsible for detecting levels of 
oxygen and carbon dioxide, as well as stretch receptors that respond to lung inflation (Mitchel, 
1980). Opioids can dose dependently produce inhibition of chemoreceptors by binding to mu and 
delta receptors. This inhibition decreases responsiveness to carbon dioxide levels resulting in 
depression of breathing that can be fatal (White & Irvine, 1999).  
Opioid-induced nausea and vomiting is reported in 25 to 40% of patients (Swegle & 
Logemann, 2006; Meuser et al., 2001). Patients report this as the most distressing side effect of 
opioid use (McNicol et al., 2003). Mu opioid receptors are abundant in the area postrema (Smith 
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& Laufer, 2014), a brainstem region responsible for detecting toxins in the bloodstream and 
triggering the vomit reflex. Even low doses of opioid analgesics activate mu receptors leading to 
nausea and vomiting.  
Sedation and sleep disturbances are another consequence of opioid use. Opioid-induced 
sedation is thought to be mediated by anticholinergic effects that can be improved through opioid 
rotation and or reduction as well as with the addition of a psychostimulant (McNicol et al., 
2003).  Although the mechanism is unknown, opioids interfere with these NTs responsible in 
mediating sleep cycles. Altering these NTs decreases the amount of time REM and restorative 
sleep and further effects arousal during wakefulness (Slatkin & Rhiner, 2004).  
Outside the CNS, opioid receptors can be found in the gastrointestinal (GI) tract.  Opioids 
binding to mu receptors in the GI tract decreases bowel motility and peristalsis, that lead to 
constipation (McNicol et al., 2003; Benyamin et al., 2008). This is the most common side effect 
of mu opioid agonists with 40% -95% of patient’s report they suffer from constipation (Kalso, 
2004). This side effect does not improve over time (Shug et al., 2003) and can occur with a 
single dose of morphine (Swegle & Lagemann, 2006). Patients suffering from constipation often 
develop hemorrhoids, bowel obstruction, and potential bowel rupture (Kurz & Sessler, 2003). 
While opioids remain the mainstay in pain management settings due to their full efficacy 
across a range of chronic pain syndromes, their side effect profile limits quality of life. Perhaps 
the most disconcerting side effect of opioids use is their ability to affect reward pathways leading 
to the development of addiction. 
Reward Pathway 
The rewarding effects of opioids have been extensively researched using the condition 
place paradigm (CPP) and rodent models of self-administration (SA).  CPP is based on principles 
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of associative learning whereby animals prefer or avoid environments previously paired with 
reinforcing or aversive drugs, respectively. SA is based on operant conditioning whereby animals 
elicit responses, such as a lever press, to receive a drug. Rewarding drugs will increase 
behavioral responses reflective of drug seeking and taking behavior. Rewarding effects of 
opiates have been largely attributed to binding with mu receptors. Agonists on mu opioid 
receptor have shown to increase opiate self-administration (O’Connor, Chapman, Butler, & 
Mead, 2010) while blocking this receptor attenuates self-administration (Weeks & Collins, 1976, 
Koob et al., 1984). This effect has also been demonstrated in CPP where mu receptor agonists 
are well known to produce place preference (Tzschentke, 1998) while mu receptor knockout 
mice do not develop opioid place preference (Matthes et al., 1996).  
The rewarding effects of mu agonists are related to structures within the 
mesocorticolimbic system that is dense with opioid receptors (Mansour, Fox, Burke, Akil, & 
Watson, 1995).  This “reward pathway” is composed of dopaminergic neurons originating in the 
ventral tegmental area (VTA) that projects to the Nucleus accumbens (NAc) and the ventral 
pallidum and are responsible for GABA release. Additional structures involved in this pathway 
are the prefrontal cortex (PFC), amygdala, and the mediodorsal thalamus and are responsible for 
glutamate release (Mansour, Fox, Burke, Akil, & Watson, 1995). The two most researched 
structures believed to be the primary source of these reinforcing effects are the VTA and the 
NAc. (Le Merrer, Becker, Befort, & Kieffer, 2009).  
The VTA and the NAc are important in relaying information about rewarding or aversive 
stimuli in the environment and motivating behavior associated with reward. Increase dopamine 
(DA) in these areas is associated with reinforcing and rewarding values of drugs of abuse 
(Spanagel & Weiss, 1999; Wise & Rompre, 1989).  Indeed, opioids indirectly increase DA levels 
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through activation of presynaptic GABA neurons that in turn inhibit GABA release in the VTA. 
GABA inhibition allows DA accumulation in the NAc causing the pleasurable effects (Johnson 
& North, 1992; (Ting-A-Kee & van der Kooy, 2012). These pleasurable effects have been 
demonstrated in a multitude of animal models. For example, blocking opioid receptors in the 
NAc has shown to decrease self- administration (Vaccarino, Bloom, & Koob, 1985). Lesions to 
both the VTA and the NAc blocks morphine SA (Smith, Guerin, Co, Barr, & Lane, 1985) and 
conditioned place preference (Bals-Kubik, Ableitner, & Shippenberg, 1993). Repeated exposure 
to opioids can lead to long term neuroadaptations of mesolimbic DA neurons that underlie 
addiction (Van Bockstaele, Reyes, & Valentino, 2010).  
DSM criterion for diagnosing addiction includes the development of tolerance, 
withdrawal, and occurs when “The substance is often taken in larger amounts and over a longer 
period than was intended” (American Psychiatric Association, 2013). Addiction is a result to 
prolonged drug exposure that causes neuroadaptations in the mesolimbic pathway, striatum, 
prefrontal cortex, hippocampus, and the amygdala. Repeated drug use produces alterations in 
signal transduction as well as decreased opioid receptor sensitivity resulting in tolerance (Dumas 
& Pollack, 2008). Tolerance is a markedly diminished drug effect whereby higher doses are 
required to achieve the initial drug response (Dumas & Pollack, 2008). Opioids inhibit the 
release of norepinephrine in the locus coeruleus. After prolong opioid use, adrenergic receptors 
are upregulated to account for the excess binding of opioids. Upon opioid cessation, the locus 
coeruleus releases an overabundance of norepinephrine precipitating withdrawal symptoms that 
include high heart rate, increase blood pressure, runny nose, tearing of the eyes, diarrhea, and 
constipation (Ballantyne & LaForge, 2007).  Because endogenous opioids are unable to maintain 
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equilibrium, the body becomes physically dependent to opioids. To prevent withdrawal 
symptoms opioid use is reinstated.   
HISTORY OF OPOIOD USE 
Opioid use dates back to 3400 BC when the Sumerians first cultivated the opium poppy 
referred to as Hul Gil or “joy plant” due to the euphoria it produced. However, the first record of 
opium poppy use to relieve pain was by Egyptians and its use spread to many other 
civilizations.  By 1170, opium had reached western medicine and was often used in surgeries 
where opium soaked rags were placed over the nose of patients undergoing surgery (Wilkerson, 
Kim, Windsor, & Mareiniss, 2016).  
 By the 19th century, opium became a key ingredient in western medicine for pain relief, 
sleep aid, and even to keep children quiet (Iverson et al., 2009). In 1805, the “inducing-factor” 
morphine was extracted from opium by German researcher Friedrich Livenstein (Rosemblaum et 
al., 2008). The industrial manufacturing of morphine followed soon thereafter but it was not until 
the invention of the hypodermic needle that morphine use became widespread. Subcutaneous 
administration of morphine allowed rapid delivery of drug and was thought to lack side effects 
produced by oral administration (Sabatowski, Schafer, Kasper, Brunsch, & Radbruch, 2004). 
Morphine use quickly rose to use during the civil war leaving many soldiers addicted at the war’s 
end.  This “soldier’s disease” brought light to the addictive qualities of morphine and led to the 
research of less addicting analgesics.  
The next shift in opioid use occurred following the synthesis of Diacetylymorphine in 
1874 by Charles Adler Wright.  Diacetylymorphine was shown to have cough suppressant 
properties in animal models (Sabatowski, Schafer, Kasper, Brunsch, & Radbruch, 2004).  
Around this time, pneumonia and tuberculosis was the leading cause of death popularizing 
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medicating with heroin. In 1898, the pharmaceutical Bayer released Diacetlymorphine registered 
under the name of heroin. Heroin was marketed as an effective pain reliever that was less 
addictive than morphine making heroin a “wonder drug”.  By 1899, Bayer was producing one 
ton of heroin a year and exporting it to 23 countries. Furthering its use, the American Medical 
Association approved heroin as a safer substitution for morphine. During this time, physicians 
noticed the addictive qualities of heroin. Without regulation, heroin use spread fast as users 
learned euphoric effects could be achieved when injected. By the early 1900s, an estimated 
300,000 people suffered from addiction with many being civil war veterans (Levinthal, 1985). 
During this time, addicts would collect scrap metal to sustain their habit coining the term 
“junkie” (Daly, 2014). Due to the rise of addiction, Bayer pulled its Diacetylmorphine off the 
market in 1911 (Courtwright, 1992).  
In response to the high rates of addiction, President Theodore Roosevelt’s administration 
set out to end to the opioid addiction crisis in the United States. At this time, the United States 
consumed more “habit-forming drugs per capita” but with fewer safeguards (Marshall, 1911). 
The Harrison Act of 1914 became the United States’ first drug law criminalizing the non-medical 
use of opium. This act made it illegal to prescribe narcotics to those who were addicted 
(“Harrison Narcotics tax act, 1914 - full text,” 1914). This act brought criminal charges to tens of 
thousands physicians resulting in imprisonment for many (Daly, 2014). Physicians that were able 
avoid prison sentences were left with tarnished medical careers. With fear of imprisonment, 
many physicians avoided treating patients with opioids resulting in the under treatment of pain 
for the next 60 years.   
The view of opioids in pain management shifted beginning in 1995 with a joint statement 
released from the American Pain Society and the American Academy of Pain Management 
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arguing physicians were under treating pain (Wilerson et al., 2016). Both groups claimed less 
than 1% of patients in pain management formed opioid addiction. This data point was taken from 
a study published in 1980 in The New England Journal of Medicine stating “the development of 
addition is rare in medical patients with no history of addiction” (Rosenblum, Marsch, Joseph, & 
Portenoy, 2008). These groups lobbied that pain should be recognized as the “fifth vital sign” 
and advocated doctors to increase opioid prescriptions (“Assessment of pain,” 2006).  Purdue 
Pharma, who helped fund the American Pain Society and the American Academy of Pain, 
released OxyContin in 1996 marking the beginning of the current opioid epidemic. 
Opioid Epidemic 
Oxycodone is a semisynthetic opioid that binds to mu opioid receptors providing relief 
for over 12 hours (“Report to congressional requesters,” 2003).  In contrast to other opioids, 
oxycodone provides the benefits of pain relief in fewer dosages and allows patients uninterrupted 
sleep.  These benefits made oxycodone a highly desirable opioid in pain management.  Indeed, in 
its first year on the market OxyContin sales reached $45 million.  In 2010, sales exceeded $3.1 
billion and accounted for 30% of opioid analgesics on the market (“Oxycontin Abuse and 
diversion and Efforts to Address the Problem,” 2013).   
Although beneficial in treating pain, the dangers of oxycodone can be dated to 1960 
when it was classified in The Dangerous Drugs (Amendment) Ordinance in 1960 by the United 
Nations (“Oxycodone,” n.d.). It was not until its release in 1996 that the abuse liability would be 
the forefront of concern. OxyContin was first marketed to physicians as a safe non-addicting 
opioid (Zee, 2009). Four years after its release, however, OxyContin was the leading drug of 
abuse in the United (Cierco, Inciardi, & Munoz, 2005).  
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The peak of the opioid epidemic was in 2010 when opioids were responsible for more 
than twice as many fatalities than both heroin and cocaine (Center for Disease Control and 
Prevention, 2013).  In 2015 alone, prescription opioids accounted for approximately 22,000 
overdose deaths (CDC, 2016) which is the equivalent of 42 deaths per day (Rudd, Seth, David, & 
Scholl, 2016). In 2012, it was estimated that up to 36 million people world-wide abused opioids 
and 2 million American are dependent on prescription opioids (Substance Abuse, 2014). Opioid 
related emergency room visits from 2004-2011 have increased by 183% (Wilkerson, Kim, 
Windosr, & Mareiniss, 2016) with OxyContin accounting for 175,949 emergency room visits in 
2009 alone (“Drug-related hospital emergency room visits,” 2011).  The economic burden opioid 
abuse in terms of loss of productivity and drug abuse treatment costs $53 to $72 billion annually 
(Hanse, Oster, & Edelsberg, 2011).  
 Despite this global epidemic, physicians continue to prescribe opioids at an alarming 
rate.  With the United States constituting around 5% of the world’s population it consumes 80% 
of the global opioid supply of oxycodone (Manchikanti & Singh, 2008).  According to the CDC, 
“Providers wrote nearly a quarter of a billion opioid prescriptions in 2013—with wide variation 
across states. This is enough for every American adult to have their own bottle of pills” (CDC, 
2016).  
TREATING OPIOID ADDICTION 
Pharmacological treatment for opioid addiction involves either opioid replacement 
therapy (ORT) or detoxification (Stotts et al., 2010).  ORT involves replacing an illegal opioid 
with an opioid that produces a weaker euphoric effect. The ultimate goal in ORT is to decreasing 
drug seeking behavior in order to stabilize patients and enroll them into behavioral therapies. 
Detoxification therapy is a medically controlled withdrawal from a drug allowing clearance of 
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opioids from the patient. During detox therapy, patients experience withdrawal symptoms of 
agitation, hot and cold flashes, nausea and vomiting that can last from hours to days (Kelber, 
2007).  There are three main classes of pharmacological treatments used in ORT and 
detoxification therapy. These classes include opioid agonists, opioid antagonists, and non-opioid 
medications.  
Opioid agonists bind to opioid receptors and mimic the effects of endogenous opiates 
(Julien, 1998). These agonists replace opioids of abuse and are utilized in both opioid 
maintenance and detoxification (Stotts et al., 2010). Most drugs of abuse produce a cycle of an 
intense short term euphoria followed by an intense “low” or crash that leads to craving initiating 
drug seeking behavior. ORT agonists produce weaker and long lasting euphoria. The goal in 
ORT is to reduce withdrawal symptoms, drug seeking behavior, and eventually taper individuals 
off agonists to reach full abstinence. Further, these medications block or decrease the euphoric 
effects of subsequent heroin or opioid use acting as competitive antagonists. The three main 
agonists used in treating opioid addiction and dependence are methadone, levomethadylacetate 
(LAAM), and buprenorphine.  
Methadone and LAAM are full opioid agonists that bind to mu opioid receptors. 
Methadone has a short half-life of 22 hours requiring daily administration while the half-life for 
LAAM is 4 days (Strain & Stitzner, 2006) and requires administration thrice weekly (Ling & 
Compton, 2005; Stotts et al., 2010).  Both methadone and LAAM are effective in treating opioid 
dependence (Johnson et al., 2000) and addiction (Longshore, Annon, Anglin, & Rawson, 2005) 
and LAAM more effective than methadone in reducing heroin use (Clark et al., 2002). However, 
many patients treated with LAAM switch to methadone due to its adverse side effects and risk of 
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cardiac ventricular arrhythmia (Wieneke et al., 2009; Clark et al., 2002) making methadone the 
first line of treatment for opioid addiction (Veilleux et al., 2010).   
While methadone and LAAM produce weak euphoria, users can become addicted to 
these compounds (Veilleux et al., 2010).  Many consider this as “replacing one addiction with 
another” (“Methadone abuse,” 2013).  In efforts to cut down on abuse and diversion, methadone 
and LAAM are classified as Schedule II drugs and are given in controlled environments 
(methadone maintenance programs). Even with tight regulation, methadone abuse is highly 
prevalent. A 2012 study reported 2.5 million people over the age of 12 reported that they abused 
methadone at one point in their lifetime (“Methadone abuse,” 2013).  In 2011, methadone 
accounted for 26% of total deaths from opioid overdoses in the United States alone (National 
Center for Health Statistics, 2014). 
Unlike methadone and LAAM, Buprenorphine is a partial agonist on mu opioid receptors 
and an antagonist at kappa opioid receptors. This buprenorphine binding profile is associated 
with fewer adverse side effects and a decrease risk of unintentional overdose compared to full 
opioid agonists (Stotts et al., 2010; Walsh, Preston, Bigelow, & Stitzer, 1995). Buprenorphine is 
classified as a Schedule III drug due to its low abuse liability and requires less monitoring than 
methadone. To further minimize its abuse liability, buprenorphine is often combined with 
naloxone which produces antagonist effects when opioids are abused (Orman & Keating, 2009; 
Whelan & Remski, 2012).  Another advantage of buprenorphine is its moderate withdrawal 
symptoms following prolong use in comparison to morphine, fentanyl, and methadone 
(Tzschentke, 2002; Walsh & Eissenberg, 2003). Buprenorphine’s long lasting effects have been 
shown to block the effects of 120 mg dose of morphine for up to 29.5 hours (Jasinski et al., 
1978). Buprenorphine’s efficacy in treating opioid addiction has met mixed reviews.  The 
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disadvantage of buprenorphine is its weak effects on mu receptors where high activity on mu 
receptors have shown higher efficacy in blocking the effects of opioids. Studies have also shown 
buprenorphine can produce euphoria in non-opioid dependent individuals with an abuse potential 
lower than a full opioid agonist (Baumevieille et al., 1997).    
A second approach to treating opioid addiction is with opioid receptor antagonists that 
block opioid binding rendering them ineffective. These antagonists are commonly used to 
accelerate detoxification (Stotts et al., 2010). The main opioid antagonist in treating opioid 
addiction and dependence is naltrexone. Unfortunately, there is a low compliance rate using 
naltrexone; up to 80% of patients drop out of naltrexone treatment within the first six months 
(Coviello, Cornish, Lynch, Alterman, & O’Brien, 2010). Further, studies have shown 
naltrexone’s efficacy is no better than placebo, buprenorphine, or addicts who do not receive 
medication (Bart, 2012; Minozzi et al., 2011).   
 Non-opioid based pharmacotherapies represents a third strategy used in opioid 
detoxification and can reduce the intensity of withdrawal symptoms. Opioids inhibit the release 
of norepinephrine in the locus coeruleus. Following prolong opioid use adrenergic receptors are 
upregulated to account for the excess binding of opioids. Upon discontinuing opioid use, the 
locus coeruleus releases an overabundance of norepinephrine precipitating symptoms of high 
heart rate, increase blood pressure, runny nose, tearing of the eyes, diarrhea, and constipation. 
Alpha-2-adrenergic agonists such as clonidine and lofexidine are commonly used to mitigate 
withdrawal symptoms through their binding in the locus coeruleus.  Both decrease release of 
norepinephrine and reduce withdrawal symptoms. Clonidine has been associated with severe 
hypotension making lofexidine the better choice in opioid detoxification therapy. 
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Prevention of Opioid Addiction 
 Much of today’s opioid crisis is attributed to the use and misuse of opioid analgesics in 
pain settings. Pharmaceutical companies are currently working on abuse-deterrent formulations 
(ADF) of opioids for pain management.  
The first abuse-deterrent strategy was the introduction of tamper resistant opioid 
formulations. Tamper resistant formulations create barriers on pills that physically and 
chemically prevent crushing or dissolving opioids. For example, Remoxy is slow release 
formulation of oxycodone in tamper proof tablets that is difficult to crush or dissolve.  However, 
this strategy has been faced with mixed success in decreasing drug abuse. In 2008, King 
Pharmaceuticals submitted Remoxy for FDA approval but their application was rejected due to 
little data supporting its ability to reduce abuse (Moorman-Li et al., 2012).  These reformulated 
compounds vary in analgesic efficacy and side effect profiles across patients that often lead 
physicians to switch or “tailor” opioid treatment following initial treatment. However, adequate 
pain management is a major challenge with only 3 tamper proof formulations approved by the 
FDA.  Further, it is unknown if these tamper resistant formulations may affect opioids efficacy 
and tolerability (Pappagallo & Sokolowska, 2012).  
A second strategy is the development of controlled-release opioid formulation. The 
concept is to produce a slow but steady release of opioids that minimizes abuse by avoiding a 
large surge in blood levels associated with euphoria. Purdue Pharma manufactured a controlled-
release formulation of OxyContin and was marketed to curb abuse liability. Unfortunately, the 
FDA was not aware that this formulation could be crushed, dissolved in water, and injected 
producing rapid absorption and euphoria. This formulation consequently increased the abuse and 
misuse of OxyContin (Rappaport, 2008).  
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The uses of agonist-antagonist opioid combinations have also been introduced as a 
potential ADF. For example, Suboxone consists of the partial mu opioid agonist buprenorphine 
and the mu inverse antagonist naloxone. Naloxone has poor oral bioavailability and does not 
interfere with the analgesic properties of buprenorphine. When Suboxone is misused by 
injection, naloxone becomes active and rapidly blocks mu opioid receptors and precipitates 
withdrawal in opioid dependent patients (Moorman-Li et al., 2012; Katz, 2008). Although 
marketed as being effective in deterring abuse, currently no data are published data to support 
these claims (Katz, 2008). 
Another ADF approach is the addition of aversive ingredients to opioids that produce 
unpleasant effects when misused. For example, adding capsaicin, a component of hot chili 
peppers, to opioids has been suggested. When consumed orally, capsaicin does not produce any 
aversive effects.   However, if crushed, snorted, or injected, capsaicin produces intense burning. 
This strategy is rarely used due to the ethical controversy of using positive punishment as a 
means mean to deter opioid abuse (Katz, 2008).  
 The use of a pro-drug opioid formulation has been suggested as a potential abuse 
deterrent approach. A pro-drug is a biological entity that is inactive until it undergoes 
biotransformation in a rate-limiting step following ingestion. This class of compounds produces 
highly desirable pharmacodynamics effects that lead to gradual increases in and stable blood 
levels for long periods of active metabolites.  There are several opioid pro-drug formulations 
developed but proof of concept studies has demonstrated the potential of such formulation to 
produce analgesic efficacy without an abuse liability.  
A major effort in the pharmaceutical industry is in the development of analgesics that 
provide for full efficacy in pain management while preventing addiction. The clinical findings to 
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date indicate this effort has proven unsuccessful.   However, a number of laboratories are 
engaged in pre-clinical research with hopes to develop opioid-based analgesic formulations that 
are void of an abuse liability but retain full analgesia across a broad spectrum of chronic pain 
conditions. 
ENDOCANNABINOIDS AND OPIOIDS IN ANALGESIA AND ADDICTION  
Cannabis sativa (marijuana) has been used for more than four centuries as an analgesic 
for a variety of pain conditions (Chiou et al., 2013). The two main constituents of cannabis are 
∆9-tetrahydrocannabinol (THC) and cannabidiol (CBD). These THC is presumed to exert 
analgesic effects by activation of cannabinoid 1 receptors (CB1R) in the CNS, and/or by 
activation of CB1R and CB2R receptors located on peripheral nerves (Chiou et al., 2013; 
Zogopoulos et al., 2008).  THC, the primary psychoactive constituent in cannabis, binds to 
CB1R and CB2R affecting sites of nociception that process and encode harmful stimuli. CBD, 
the non- psychoactive constituent in cannabis, has a limited binding affinity to either CB1R or 
CB2R but is known to play a role in immune responses as well as nociception (Ameri, 1998; 
Nurmikko et al., 2007; Rahn and Hohmann, 2009; Chiou et al., 2013). When administered 
systemically, cannabinoids produce analgesic properties comparable to opioids in acute pain 
models (Chiou et al., 2013; Walker et al., 2001).   
Studies have shown that opioid analgesia can be potentiated by cannabinoids producing 
supra-additive analgesic effects in a number of pain assays. For example, combinations of CBD 
or THC and morphine displayed synergistic effects in a murine abdominal writhing assay 
(Neelaktantan et al., 2014) and in arthritic models (Cox et al., 2007). THC has also shown to 
increase the antinociceptive properties of morphine in rodent tail-flick assays (Welch & Stevens, 
1992). These effects are mediated by signaling interactions of CB1R and mu-opioid receptors co-
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expressed in brain structures that modulate nociceptive responses (Wilson-Poe et al., 2008; 
Mansour et al., 1988) through a descending pain control circuit (Basbaum et al., 1984).  
Cannabinoids, Opioids, and Reward 
CB and opioid receptors are known to play a role in the reinforcing effects of drugs of 
abuse as demonstrated in a variety of rodent addiction models. The reinforcing effects of THC 
and opioids have been extensively researched in CPP. While THC and mu-agonists produce 
place preference, (Braida, Iosuè, Pegorini, & Sala, 2004; Lepore, Vorel, Lowinson, & Gardner, 
1995; Tzschentke, 1998) antagonizing either receptor can influence these rewarding effects. For 
example, antagonizing CB1 receptors has been shown to block morphine place preference (Mas-
Nieto et al., 2001). In addition, mu-opioid receptor KO mice receiving THC do not display place 
preference (Ghozland et al., 2002). These data suggest opioid and cannabinoid receptors interact 
to modulate rewarding effects of either drugs.  
The activity of opioid and CB receptors in addiction has also been modeled in the rodent 
SA paradigm. Like drugs of abuse, CB1R agonists produce rewarding effects by increasing 
dopamine in the mesolimbic pathway producing pleasurable effects (Tanda, Pontieri, & Di 
Chiara, 1997). Animals exposed to THC show an increased self-administration of heroin 
(Solinas, Panlilio, & Goldberg, 2004) while antagonizing these CB1 receptors reduce heroin self-
administration (Navarro et al., 2001). Further, morphine self-administration is reduced in CB1R 
knockout mice (Ledent et al., 1999). Taken together, CB1R agonists possess the ability to 
increase the abuse potential of opioids.  
Unlike CB1Ragonists, CB2R agonists decrease dopamine in the ventral tegmental area 
and has shown to reduce the rewarding effects of drugs of abuse (Zhang et al., 2014). For 
example, agonizing CB2R reduces cocaine self-administration in mice (Xi et al., 2011; Zhang et 
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al., 2014). A similar effect on cocaine SA is seen in mice with overexpression of CB2R (Aracil-
Frenandez et al., 2012). These data demonstrate CB2R agonists show potential in decreasing 
rewarding effects of opioids. Collectively these findings suggest reinforcing effects of drugs are 
mediated by localization of opioid and cannabinoid receptors. Further, CB1R agonists facilitate 
the reinforcing effects opioids while CB2R agonists mitigate these effects.  
Recent research using an intracranial self-stimulation (ICSS) paradigm investigated 
CBD’s effect on morphine reward. ICSS is an operant paradigm that allows rodents to self-
administer rewarding electrical stimulation via electrodes implanted in the brain. Katsidoni and 
colleagues demonstrated CBD blocked the reward-facilitating effects of morphine on ICSS 
endpoints (Katsidoni, Anagnstou, & Panagis, 2012). The mechanisms that underlie these effects 
is unknown given CBD’s low binding affinity to CB1Rs and CB2Rs.  Nevertheless, the ability of 
CBD to decrease the rewarding effects of morphine in the ICSS model, this compound may have 
important abuse-deterrent properties in pain management settings. 
It is unknown whether a CBD-opioid pharmacotherapy possesses qualities that prevent 
opioid abuse while retaining analgesic properties. The goal of this research is to determine 
whether CBD and a CBD derivative prevent opioid abuse while retaining analgesic properties. 
Such findings would lead to possible opioid formulations for use in pain management settings  
and mark the beginning of the end of prescription-initiated opioid addiction.  
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Ethical Considerations and IACUC Approval 
 All experiments were conducted in accordance with the American Psychological 
Association guidelines for the ethical treatment of nonhuman subjects and the policies of the 
University of Mississippi. All experiments described below have received approval by the 
University of Mississippi’s Institutional Animal Care and Use Committee (IACUC) under 
protocol 15-022 on 18 May 2015.  
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CHAPTER II 
 
PILOT STUDIES 
Introduction 
CBD has shown to mitigate morphine reward in a rodent model of intracranial self-
stimulation (ICSS) (Katsidoni et al., 2013).  Many paradigms model the development and 
maintenance of addition including intravenous (IV) self-administration and the condition place 
preference (CPP) paradigm. It is unknown if CBD actions on morphine reward can generalize to 
other models quantifying abuse liability. Therefore, this research sought to determine if CBD 
could attenuate morphine reward in a CPP paradigm.  
Method  
Subjects  
C57BL/6 male mice (25-30 g) were group housed (n = 5) in a polycarbonate tub with soft 
bedding in a temperature and humidity controlled vivarium. Mice were maintained under a 12:12 
hour light/dark cycle with lights on at 06:00. Food and water were available ad libitum. Mice 
acclimated to the vivarium colony room one week prior to behavioral testing. All experimental 
procedures were approved on 18 May 2015 by the Institutional Animal Care Committee at the 
University of Mississippi (Protocol # 15-022).  
Apparatus  
Five place preference chambers (Model MED-CPP-3013; Med Associates, St. Albans, 
VT) were used for these experiments.  Each chamber has two stimulus-distinct conditioning 
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chambers (Black versus white colored walls and wire or mesh metal rod flooring; 16.75X12.70 
cm) separated by a third central start chamber (7.25X12.70 cm; colored grey with a smooth solid 
floor). Guillotine doors permitted confinement/access to individual chambers.   
Procedure 
The groups in this study formed a 2x5 factorial design that combined 2 levels of 
morphine (saline and 2.5 mg/kg morphine) and 5 levels of CBD (vehicle and 4 doses). Morphine 
Sulfate (Research Biomedical International; Natick, MA) was dissolved in 0.9% saline to yield a 
dosage of 2.5 mg/ml. Cannabidiol (>98% purity) solutions of 2.5, 5.0, 10.0, and 20.0 mg/kg/mL 
(ELI Laboratories; Oxford, MS) were dissolved in a 5% ethanol/5% cremophor solution of 
injectable water.  Mice received dual IP administrations of test compounds in a volume of 1 
ml/kg. 
Prior to behavioral testing, animals were allowed to acclimate to the testing room for at 
least 30 minutes. The CPP procedure consists of four phases: 1) a 15 min apparatus habituation 
trial, 2) a 15 min trial to establish baseline CPP scores, 3) six 45 min drug conditioning trials, 
and 4) a 15 min trial to establish post-conditioning CPP score. During the drug free habituation, 
baseline, and final preference trials animals were placed in the gray start chamber for a 5 minute 
adaption period. Following the adaption period, the guillotine doors were lifted allowing access 
to the entire apparatus.  The test apparatus was thoroughly cleaned with 70% ethanol solution 
after each trial.   
 CPP scores were determined by  
  	

  	

  and led to the establishment of the 
S+ chamber for drug conditioning whereby S+ assigned to the non-preferred compartment.  
From these CPP scores, baseline and post-conditioning scores were quantified as  
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 .  
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Preference scores were calculated by taking subtracting post-conditioning and baseline CPP 
scores with positive values reflecting reward and negative values reflecting aversion.  
Statistical Analyses 
Data were analyzed using SPSS software using two-way (between groups) ANOVA and 
one-way (between groups) ANOVA for simple effects analyses followed by planned 
comparisons (Fisher’s LSD) for groups differences with significance at p < 0 .05. 
Results 
The effects of CBD on morphine conditioned place preference scores are summarized in 
Figure 1. Preference scores were near zero in the control group (vehicle + saline) indicating there 
was little change in baseline and post-conditioning CPP scores. Morphine treated animals 
showed higher preference scores compared to the control group. Among the saline groups, CBD 
did not show neither place preference nor aversion. Among the morphine groups, CBD dose-
dependently decreased preference scores with a max effect at 10 mg/kg CBD.  
A two-way ANOVA revealed a significant main effect for Morphine F(1,78) = 30.04, p < 
0.001. The main effect for Cannabidiol and the Cannabidiol x Morphine interaction were not 
significant F(4,78) = 1.57, p = 0.19; F(4, 78) = 1.68, p =0.16 respectively. To determine whether 
morphine possessed place preference, a one-way ANOVA of the Vehicle groups were conducted 
and revealed a significant effect for Morphine F(1,15) = 15.69, p < 0.001. To test whether CBD 
possessed rewarding or aversive properties, a one-way ANOVA among the Saline groups found 
no significant treatment effect F(4,39) = 1.21, p = 0.32. In order to determine whether CBD 
attenuated opioid reward, a one-way ANOVA on morphine groups were performed and found a 
treatment effect that approached significance F(4,37) = 2.30, p = 0.077.  
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Planned comparisons among the morphine groups found 10.0 mg/kg had significantly 
lower preference scores than the CBD vehicle (p = 0.033).  
Discussion  
 The challenge in pain management is to deliver analgesic treatment that is fully 
efficacious but also void of abuse liability. The present research shows CBD can attenuate opioid 
reward without producing aversion or reward by itself. These findings suggest that a CBD-opioid 
formulation may be void of abuse liability and useful in pain management settings.  
Although capable of attenuating morphine reward, CBD is not without several 
translational challenges. Among these may be the poor absorption of CBD when given by enteral 
administration. Research to enhance CBD bioavailability through chemical modification led to 
the development of a CBD derivative (cannabidiol mono valine mono hemisuccinate: CBD-val-
HS) that possess characteristics that may be useful in clinical populations. This derivative is 
readily absorbed within 30 minutes of administration and that stable and biologically relevant 
blood levels persist beyond 12 hrs post administration. Whether this CBD derivative can 
attenuate rewarding properties of opioids and retain analgesic properties is unknown.   
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CHAPTER III 
 
EXPERIMENT 1: PLACE PREFERENCE ASSAY 
Introduction 
The purpose of this study was to identify whether CBD-val-HS can attenuate opioid 
reward without producing aversion or reward in the CPP paradigm. In this study we selected 
oxycodone as the opioid probe because it is a more clinically relevant compound in pain 
management settings and a drug frequently abused among opioid addicts. We predict oxycodone 
will produce place preference that will be dose-dependently attenuated by CBD-val-HS. Further, 
we predict CBD-val-HS, when given alone, will not produce place preference nor aversion. 
Method 
Subjects and apparatus were as described in the pilot study. 
Procedure 
The groups in this study formed a 2x5 factorial design that combined 2 levels of 
oxycodone (saline and 3.0 oxycodone) and 5 levels of CBD-val-HS (vehicle and 4 doses). 
Oxycodone (Tocris, Boston, MA) was dissolved in 0.9% saline to yield a dosage of 3.0 mg/ml. 
CBD-val-HS 7.0, 8.0, 12.0, 16.0 mg/kg (ELI Laboratories; Oxford, MS) were dissolved in a 
solution of 5% ethanol/5% cremaphor of injectable water.  Mice received sequential dual IP 
injections of test articles in a volume of 1 ml/kg. 
The details of the CPP procedure was as described in the pilot study.  
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Statistical Analyses 
Data were analyzed using SPSS software using two-way (between) ANOVA and one-
way (between groups) ANOVA for simple effects followed by planned comparisons with 
significance at p < 0.05.  
Results 
The effects of CBD-val-HS on oxycodone conditioned place preference scores are 
summarized in Figure 2. Preference scores were near zero in the control group (vehicle + saline) 
indicating there was little change between baseline and post-conditioning CPP scores. 
Oxycodone treated animals showed higher preference scores compared to the control group. 
Among the saline groups, CBD-val-HS did not show place preference nor aversion. Among the 
oxycodone groups, CBD-val-HS dose-dependently decreased preference scores with a maximum 
effect at 8 mg/kg.  
A two-way ANOVA of these CPP data revealed a significant main effect for 
Cannabidiol-val-HS and the Cannabidiol-val-HS x Oxycodone interaction F(4,129) = 1.203, p = 
0.025; F(4, 129) = 1.541, p =0.32 respectively. The main effect for Oxycodone was not 
significant F(1,129) = 16.331, p = 0.337. To determine whether oxycodone possessed place 
preference, a one-way ANOVA of the Vehicle groups were conducted and revealed a significant 
effect for Oxycodone F(1,24) = 10.784, p = 0.003. To test whether CBD-val-HS possessed 
rewarding or aversive properties, a one-way ANOVA among the saline groups found no 
significant treatment effect F(4,66) = 1.461, p = 0.224. In order to determine whether CBD-val-
HS attenuated opioid reward, a one-way ANOVA on oxycodone groups found no significant 
treatment effect F(4,63) = 1.22, p = 0.310. Planned comparisons among the oxycodone groups 
found 8.0 mg/kg CBD-val-HS had significantly lower preference scores than vehicle (p = 0.033).  
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Discussion 
 The present study sought to determine whether the CBD derivative, CBD-val-HS, could 
alter the development of oxycodone reward in the condition place preference paradigm.  As 
predicted, 3.0 mg/kg oxycodone produce robust place preference indicative of reward. This 
finding is consistent with literature demonstrating opioids such as morphine produce preference 
in the CPP paradigm (Prus et al., 2009).  
 CBD-val-HS attenuated the rewarding effects of oxycodone place preference with a dose 
of  8.0 mg/kg. Further, this novel derivative itself is void of reward or aversive properties. This 
finding is consistent with previous research in this lab demonstrating CBD can alter morphine 
place preference and void of an aversive effect. Although the mechanism of action is unknown, 
the behavioral effects of CBD-val-HS in this model resemble that of CBD and strongly argue 
that these compounds carry out the same mechanism of action. 
Taken together, results from these CPP studies align with reports that CBD also blocks 
opioid reward in the ICSS paradigm (Katsidoni et al., 2013) and a literature that CBD itself lacks 
hedonic or aversive actions (Mechoulam et al., 2002; Mechoulam et al., 2007; Parker et al., 
2004). These findings suggest CBD-val-HS may translate well as a useful pharmacotherapy in 
preventing substance abuse. Further, the absence of of psychotomimetic properties of CBD-val-
HS should abate concerns raised by substitution therapies like methadone maintenance programs.  
 Much of today’s opioid epidemic is attributed to overuse of prescription opioids in pain 
management and CBD-val-HS may also show efficacy here as an abuse deterrent in a dual drug 
formulation. Indeed, few alternatives exist for effective pain management outside of opioids and 
there are attempts to develop dual drug formulations that mitigate opioid reward while 
maintaining the full analgesic profile (Townsend et al., 2017). There is evidence to suggest that a 
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CBD opioid formulation would possess such an analgesic profile. Neelakantan et al. (2015) 
reported that a CBD-opioid combination possesses synergistic analgesia in the abdominal 
writhing assay. Whether a CBD-val-HS + opioid formulation possess robust analgesia across a 
range of nociceptive assays remains to be determined.  
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CHAPTER IV 
 
EXPERIMENT 2: NOCICEPTIVE ASSAYS 
Introduction 
 Like non-opioid therapies, the biggest challenge for CB compounds as analgesics is in 
their modest efficacy. Combination of opioid and CB receptor agonists has shown synergistic 
effects in a number of pain assays. This synergistic effect is thought to be mediated by signaling 
interactions of CB1 and mu-opioid receptors co-expressed in brain structures that modulate 
nociceptive responses (Wilson-Poe et al., 2008; Hall et al., 2005; Mansour et al., 1988) through a 
descending pain control circuit (Basbaum et al., 1984).   Neelkatantan et al., demonstrated 
combinations of CBD and morphine could produce synergistic analgesic effects in a murine 
abdominal writhing assay. However, these combinations have produced sub-additive nociceptive 
responses in models of thermal nociception (Neelaktantan et al., 2014).  
Studies in this laboratory have shown that CBD in combination with a sub-analgesic dose 
of morphine can produce synergistic analgesic effects on tactile allodynia in murine model of 
cisplatin induced neuropathy (CIN). Further studies in this CIN model have shown that 1) CBD-
val-HS in combination with a sub-analgesic dose of morphine and 2) CBD-val-HS administered 
alone can produce robust pain relief equivalent to a fully efficacious dose of morphine. 
Whether CBD-val-HS acts and interacts with opioids in a manner similar to CBD in the 
aforementioned thermal and inflammatory nociceptive assays is unknown. Thus, the next set of 
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experiments examined the analgesic properties of CBD-val-HS given alone and in combination 
with increasing doses of oxycodone on the hotplate and abdominal writhing assays.   
Method 
Subjects  
Animal characteristics and housing conditions were as described earlier.  
Procedure  
These experiments formed a 2x3 factorial design which entailed two levels of CBD-val-
HS (cremaphor and 8.0 mg/kg) and three levels of oxycodone (saline, 1.0 and 3.0 mg/kg 
oxycodone) with 9-17 animals per experimental condition. Oxycodone (Tocris, Boston, MA) 
was dissolved into saline the first day of testing. CBD-val-HS 8.0 mg/kg (prepared by ELI 
laboratories; Oxford, MS) was kept refrigerated and brought to room temperature prior to 
administration. Mice received sequential dual IP injections of test articles in a volume of 1 
ml/kg. 
A hotplate apparatus (Harvard Instruments, Model #52-8570) was used to quantify 
thermal nociception. This consisted of an open top acrylic enclosure (12.7 X 15.24 cm) 
positioned on a plate heated set to 52oC. A digital timer operated via a foot switch measured the 
latency of a nociceptive response (i.e., hind paw flutter, lick, or an escape response) and 
presented on a digital display. Mice were given IP injections of test articles and transported to 
the testing room 30 minutes prior to behavioral testing for acclimation to the experiment room. 
Mice were then placed onto the hotplate and immediately removed following a nociceptive 
response or after a 45 second cut-off to prevent tissue damage. Following thermal nociceptive 
testing, animals were given a no-drug/test-free week then enrolled into acetic acid writhing 
assay.  
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Acetic acid writhing testing was used to quantify inflammatory nociception. Testing was 
conducted in clear, open-top, acrylic observation chambers (12.7 X 15.24 cm) located on a 
smooth surface. Mice were given IP injections of test articles and transported to the testing room 
30 minutes prior to behavioral testing for acclimation to the experiment room. For testing, mice 
were then given an IP injection of 0.7% acetic acid in a volume of 10 ml/1kg and immediately 
placed in an observation chamber for 30 minute test.  The number of abdominal stretches served 
as the dependent measure. Following testing, animals were returned to home cage and 
euthanized via Euthasol at the completion of the experimental test session.  
Statistical Analyses 
Data was analyzed using SPSS software using two-way (between group) ANOVA and 
one-way (between groups) ANOVA for simple effects analyses followed by planned 
comparisons for group differences with significance at p < 0 .05. In case of unequal variances 
(assessed by Levene’s test), analyses were performed on square-root transformed count data. If 
main effects or interactions were significant, data were further analyzed by one-way ANOVA 
and Fisher’s LSD post hoc tests.   
 Previous research has reported that around 16% of mice do not respond to acetic acid 
and 23% of mice display one writhe after a sham injection (Collier et al., 1968). Data was 
screened for non-responders and outliers prior to analysis. This amounted to the removal of 2 
non-responders per group in addition to removing animals with less than 5 writhes.   
Results 
The effects of oxycodone and CBD-val-HS on hotplate responses are summarized in 
Figure 3. Vehicle and the sub-analgesic dose of oxycodone (1.0 mg/kg) did not affect hotplate 
responses whereas the 3.0 mg/kg oxycodone produced robust analgesia demonstrated with high 
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response latencies. CBD-val-HS alone produced response latencies equivalent to 3.0 mg/kg 
Oxycodone.  Further, the sub-analgesic and analgesic doses of oxycodone given in combination 
with CBD-val-HS produced sub-additive effects on hotplate latencies. 
 Consistent with these observations, a two-way ANOVA performed on these data 
revealed a significant main effect for Oxycodone, F(2,76)= 3.830, p = 0.026 and a significant 
CBD-val-HS  x Oxycodone interaction F(2,76)= 5.761, p = 0.005. The CBD-val-HS term was 
not significant F(1,76)= 0.49, p = 0.619. To determine which oxycodone dose produced 
analgesia, a one-way ANOVA of the vehicle groups were conducted and revealed a significant 
effect for Oxycodone F(2,40)= 6.467, p = 0.004. Post hoc analyses among the cremaphor groups 
found 3.0 mg/kg oxycodone produced significantly higher hotplate response latencies than saline 
and 1.0 mg/kg oxycodone (p = 0.001). To test whether CBD-val-HS produced analgesia, a one-
way ANOVA among the saline groups was conducted and revealed a significant main effect for 
CBD-val-HS F(1,35) = 6.273, p = 0.017. 
To determine whether CBD enhanced oxycodone analgesia, a one way on the CBD-val-
HS groups were conducted and revealed a significant main effect F(2,36) = 3.674, p = 0.035. 
Post hoc analysis among these groups revealed 8.0 mg/kg CBD-val-HS + 1.0 mg/kg oyxcodone 
produced a significantly lower hotplate response latency than 8.0 mg/kg CBD-val-HS (p 
=0.010). There was no significant difference between 8.0 mg/kg CBD-val-HS and 8.0 mg/kg 
CBD-val-HS+ 3.0 mg/kg oxycodone (p > 0.230).  
The effects of oxycodone and CBD-val-HS on abdominal writhing responses are 
summarized in Figure 4.  Oxycodone produced a dose-dependent decrease in writhing response 
indicative of analgesia.  In the Saline treated groups, CBD-val-HS also attenuated writhing 
illustrating this CB derivative possesses analgesic properties against inflammatory nociception. 
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CBD-val-HS in combination with increasing doses of oxycodone appears to produce additive 
effects in attenuating abdominal writhes.  
A two-way ANOVA was carried out, and as Levene’s test for equality of variances was 
significant, data were transformed using log square root. This analysis revealed a significant 
main effect for Oxycodone, F(2,52)=22.939,  p <0.001 and a significant main effect for CBD-
val-HS F(2,52)=46.082, p <0.001. The CBD-val-HS x Oxycodone interaction term was not 
significant F(2,52)= 0.440, p = 0.646. To determine which oxycodone dose decreased abdominal 
writhes, a one-way ANOVA of the vehicle groups were conducted and revealed a significant 
main effect for Oxycodone F(2 ,25)= 23.534, p <0.001. Post hoc analyses among these groups 
found 3.0 mg/kg oxycodone produced significantly lower abdominal writhes than saline and 1.0 
mg/kg Oxycodone (p <0.001). To test whether CBD-val-HS produced decreased writhing, a one-
way ANOVA among the saline groups was conducted and revealed a significant main effect for  
CBD-val-HS F(1,19 ) = 5.943, p =0.025. 
To determine whether CBD enhanced oxycodone analgesia, a one way on the CBD-val-
HS groups were conducted and revealed a significant effect for CBD-val-HS F(2,27) =23.454, p 
<0.001. Post hoc analysis among these groups demonstrated 3.0 mg/kg oxycodone + CBD-val-
HS significantly decreased abdominal writhing (p <0.001). 
Discussion 
 Experiments 2 and 3 sought to determine whether a dose of CBD-val-HS that blocks 
opioid reward administered alone or in combination with a sub-analgesic or analgesic doses of 
oxycodone would affect nociceptive processes in the hotplate and abdominal writhing assays.  
  As expected, 3.0 mg/kg oxycodone was robust in increasing hotplate response latency 
and decreasing abdominal writhing responses while 1.0 mg/kg oxycodone was ineffective in 
both assays. These responses are consistent with previous literature demonstrating high dose 
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opioids such as oxycodone produce analgesic responses in both supraspinal thermal assays as 
well as peripheral inflammatory pain (Watson et al., 2003; Yao et al., 2012). CBD-val-HS alone 
produced analgesic effects in both assays but was most effective when compared to oxycodone 
against thermal nociception.  Interestingly, there was a differential interaction of CBD-val-HS 
and oxycodone across the two nociceptive assays. Subadditive responses were observed in the 
hotplate assay while additive responses were observed in the abdominal writhing assay.  
Data from the hotplate assay are consistent with Neelkanatan et al., who demonstrated 
CBD in combination with an opioid (morphine) produce subadditive effects (2015). Unlike 
CBD, CBD-val-HS produced robust analgesia equivalent to high dose Oxycodone. These 
responses are most likely due to a superior absorption profile allowing binding to pain regulating 
sites include the periaqueductal gray (PAG), thalamus, amygdala, spinal cord and/or the 
peripheral nervous system which modulates inflammatory pain by affecting factors involved in 
inflammation (Rahn and Hohmann, 2009; Chiou; Zogopoulos et al., 2008; Pertwee, 2001).  
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CHAPTER V 
 
GENERAL DISCUSSION 
 
Opioid use for chronic pain syndromes has seen significant growth in the last several 
decades. The perception that newer opioids possessed little abuse liability in pain management 
settings has led to the opioid abuse crisis we experience today (Kaye et al., 2017). These opioids 
in various novel formulations were marketed to physicians as non-addictive without clear and 
compelling evidence.  It is estimated that of the 60% overdose deaths in the United States in 
2014, over 28,647 can be linked to an opioid prescription to treat pain (CDC, 2016). Currently, 
several states have or are in the process of filing lawsuits against Purdue Pharma and other 
pharmaceutical companies for false marketing (Semeuls, 2017) in an attempt to recover 
associated costs of opioid abuse.  While there are continued attempts to formulate full efficacy 
opioids void of abuse liability, these efforts have met with little success (Moorman-Li et al., 
2012; Pappagallo & Sokolowska, 2012; Rappaport, 2008; Katz, 2008). The work herein 
demonstrates in a preclinical model that a cannabidiol derivative + oxycodone combination is 
formulation that would achieve high efficacy in treating pain yet be void of abuse liability.  
 One additional finding from this research was that cannabidiol-val-HS possesses 
significant analgesic properties against acute thermal and persistent inflammatory nociception.  
This work aligns well with earlier work form this laboratory that shows CBD-val-HS possess 
analgesic activity in a murine model of chemotherapy induced neuropathy (CIN; Harris, 2017).  
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Against acute thermal nociception and CIN, CBD-val-HS analgesic effects are as efficacious as 
oxycodone and morphine, respectively. Collectively, these studies suggest it may be unnecessary 
to rely on an opioid x CBD-val-HS formulation to treat certain pain conditions. An important 
unanswered question is whether CBD-val-HS possesses analgesic activity across a broad range 
of other pain conditions including, among others, arthritic, cancer, and migraine models. 
There are a number of additional research questions that would facilitate the movement 
of this compound through the drug discovery pipeline and enter into clinical trials. The first step 
would entail experimental designs to perform isobolographic analyses. Isobolograms are the gold 
standard in studying drug-x-drug interactions and determine whether a compound possesses 
subadditive, additive, or synergistic properties. These data identify relevant doses of each 
compound necessary to achieve full clinical efficacy.  As certain opioids may be more 
efficacious against specific pain conditions, it may be necessary to perform isobolograms across 
a broad range of opioids with this novel CBD derivative to create a set of novel formulations 
tailored to treating a wide variety of chronic pain conditions. 
As with any novel therapeutic, its use may be limited by adverse side effects. Future 
research should explore the possibility that a CBD-val-HS formulation with opioids produce 
undesirable effects that might limit its use. While the current research demonstrates the most 
serious issues of opioid addiction is mitigated by CBD-val-HS, it will be important to test this 
formulation in assays that assess sedation, ataxia, respiratory depression, and other physiological 
side effects. We believe it is unlikely that CBD-val-HS as a stand-alone analgesic will possess 
such characteristics as its parent molecule CBD does not show any adverse side effects 
(America, 1998). Indeed, CBD has demonstrated to be safe and effective for use in epilepsy and 
is in current use today for this debilitating condition. We assume this modest chemical  
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variation that enhances bioavailability will possess a similar safety and efficacy profile.  
Perhaps the most intriguing scientific question unanswered is how CBD-val-HS acts on 
nervous system targets that differentially modulates both nociception and addiction. Little is 
known about the CNS action of CBD but the patterns of CBD-val-HS show similar effects on a 
wide variety of behavioral endpoints. A full screen across CNS receptors may reveal CBD-val-
HS has selectivity to a number of non-CB receptors or, perhaps, lack receptor selectivity 
altogether.  Future mechanism of action studies may show that CBD-val-HS acts on nervous 
system activity that interfere with intracellular communication process that maintains normal 
neuronal functioning. Regardless of the exact mechanism of action, that a CBD-val-HS x opioid 
formulation can interfere with reward processes while enhancing analgesia represent a 
significant turning point in the opioid abuse crisis today.  
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Figure 1.  The effects of CBD on morphine place preference scores. Values represent difference 
in the mean ratio of time (seconds) spent in the S+ (drug-paired) chamber during pre- and post-
condition trials. Open bars reflect saline treated animals and striped bars represent morphine 
treated animals. *denotes significant difference form the vehicle group. † denotes significant 
attenuation of morphine preference. Sample sizes were n= 7-10.  
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Figure 2. The effects of CBD-val-HS on oxycodone place preference scores. Values represent 
difference in mean ratio of time (seconds) spent in the S+ (drug-paired) chamber during pre-and 
post- condition trials.  Opens bars reflect saline treated animals and hatched bars represent 
oxycodone treated animals. * denotes significant difference from the vehicle group. † denotes 
significant attenuation of oxycodone preference. Sample sizes were n = 11-15. 
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Figure 3. The effects of CBD-val-HS and oxycodone on hotplate response latencies. Values 
represent the mean latency (seconds) of a hind-paw lick or flutter.  * denotes a significant 
difference from the saline group.  Sample sizes were n= 9-17. 
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Figure 4. The effects of CBD-val-HS and oxycodone in the abdominal writhing test.  Values 
represent the mean number of writhes following an intraperitoneal injection of 0.7 % acetic acid 
over a 30 minute test session. * denotes a significant difference from the saline group.  † denotes 
a significant difference from oxycodone 3.0 mg/kg.  Sample sizes were n= 8-15.
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